ArticleAntimicrobial agents and chemotherapy2020
Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Hepatoprotective Mechanism of Shorea Robusta Gaertn. f. Against Isoniazid-induced Hepatotoxicity by Targeting TNF-α, TGF-β1, and PPAR-α: Insights from Computational Profiling To Immunohistochemical Confirmation.Cell biochemistry and biophysics · 2026Article
- TheMicrobiology spectrum · 2026Article
- A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference inACS infectious diseases · 2025Article
- Isoniazid-Derived Hydrazones Featuring Piperazine/Piperidine Rings: Design, Synthesis, and Investigation of Antitubercular Activity.Biomolecules · 2025Article
- Isoniazid-rhodanine molecular hybrids: design, synthesis, antimycobacterial activity and computational validation.RSC advances · 2025Article
- Genomic characterization of multidrug-resistant tuberculosis in Shanghai, China: antibiotic resistance, virulence and transmission.JAC-antimicrobial resistance · 2025Article
- Secondary Metabolites from a New Antibiotic-Producing Endophytic Streptomyces Isolate Inhibited Pathogenic and Multidrug-ResistantTropical medicine and infectious disease · 2025Article
- Decoding drug tolerance: insights into theFrontiers in microbiology · 2025Article
- Toward better cures forClinical microbiology reviews · 2024Review
- Breaking barriers: The potential of nanosystems in antituberculosis therapy.Bioactive materials · 2024Review
- Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nature reviews. Drug discovery · 2024Review
- MarR-Dependent Transcriptional Regulation ofAntimicrobial agents and chemotherapy · 2023Article
- Noncanonical Mismatch Repair Protein NucS Modulates the Emergence of Antibiotic Resistance in Mycobacterium abscessus.Microbiology spectrum · 2022Article
- Variability ofAntibiotics (Basel, Switzerland) · 2022Review
- Isoniazid Linked to Sulfonate Esters via Hydrazone Functionality: Design, Synthesis, and Evaluation of Antitubercular Activity.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Deciphering Isoniazid Drug Resistance Mechanisms on DimericACS omega · 2022Article
- HupB, a nucleoid-associated protein, is critical for survival ofFrontiers in microbiology · 2022Article
- Tibetan medicine salidroside improves host anti-mycobacterial response by boosting inflammatory cytokine production in zebrafish.Frontiers in pharmacology · 2022Article
- Review
- Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline.PLoS pathogens · 2021Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isoniazid (INH) is a cornerstone of antitubercular therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.